TI
ADVM

Trexquant Investment’s Adverum Biotechnologies ADVM Stock Holding History

Trexquant Investment’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,694
Closed -$81.7K – 1486
2025
Q1 		$81.7K Sell
18,694
-77,303
-81% -$348K ﹤0.01% 1508
2024
Q4 		$448K Buy
95,997
+60,163
+168% +$405K 0.01% 1311
2024
Q3 		$252K Buy
+35,834
New +$260K ﹤0.01% 1393
2021
Q1 		– Sell
-1,188
Closed -$129K – 1082
2020
Q4 		$129K Buy
+1,188
New +$147K 0.01% 951
2018
Q2 		– Sell
-3,164
Closed -$184K – 861
2018
Q1 		$184K Buy
+3,164
New +$197K 0.01% 961
2016
Q2 		– Sell
-3,223
Closed -$167K – 836
2016
Q1 		$167K Buy
3,223
+1,568
+95% +$87.6K 0.02% 853
2015
Q4 		$158K Sell
1,655
-1,765
-52% -$155K 0.01% 955
2015
Q3 		$281K Buy
+3,420
New +$437K 0.02% 891
2015
Q2 		– Sell
-2,600
Closed -$1.05M – 953
2015
Q1 		$1.05M Buy
+2,600
New +$1.1M 0.11% 339

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Trexquant Investment's ADVM Position: Q2 2025 in Review

Trexquant Investment sold out of Adverum Biotechnologies (ADVM) in Q2 2025, closing a stake of 18,694 shares — an estimated $81.7K sold.

Trexquant Investment first reported a position in ADVM in Q1 2015 and held it in 9 quarters. The position peaked at $1.05M in Q1 2015. 58 funds tracked by Wall St. Rank hold ADVM as of Q2 2025.

  • Trexquant Investment reported no remaining Adverum Biotechnologies position as of Q2 2025 after selling out during the quarter.
  • Trexquant Investment sold 18,694 Adverum Biotechnologies shares in Q2 2025, an estimated $81.7K.
  • Trexquant Investment first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 9 quarters.
  • Trexquant Investment's Adverum Biotechnologies position peaked at $1.05M in Q1 2015.
  • 58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2025.

Based on Trexquant Investment's 13F filing for Q2 2025, filed 12 Aug 2025.